Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Product dose omission issue? 5,873 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5,873 reports of Product dose omission issue have been filed in association with MEPOLIZUMAB (Nucala). This represents 13.7% of all adverse event reports for MEPOLIZUMAB.

5,873
Reports of Product dose omission issue with MEPOLIZUMAB
13.7%
of all MEPOLIZUMAB reports
88
Deaths
957
Hospitalizations

How Dangerous Is Product dose omission issue From MEPOLIZUMAB?

Of the 5,873 reports, 88 (1.5%) resulted in death, 957 (16.3%) required hospitalization, and 24 (0.4%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 5,873 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656) Off label use (2,614)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460) GOLIMUMAB (4,216)

Which MEPOLIZUMAB Alternatives Have Lower Product dose omission issue Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue MEPOLIZUMAB Demographics